- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Fr | RFK Jr.'s hand-picked panel questions childhood vaccine schedule | ||
| Fr | Hemophilia gene therapies are struggling on the market, even as innovation soars | ||
| Fr | Praxis soars higher; Bristol Myers' CAR-T therapy wins broader use | ||
| Do | CDC panel again postpones vote on newborns' hepatitis B shot | ||
| Do | An Arch-backed biotech raises $53M to fight neurodegeneration | ||
| Do | 12 former FDA chiefs blast Prasad's move to toughen vaccine standards | ||
| Do | Tracey Beth Høeg, top Makary deputy, named head of FDA drug office | ||
| Do | UniQure slides further on outlook for Huntington's gene therapy | ||
| Mi | After finding 'irregularities,' Bristol Myers to extend key trial of Cobenfy in Alzheimer's psychosis | ||
| Mi | Capricor soars on positive results for Duchenne cell therapy | ||
| Mi | Pharvaris' pill succeeds in late-stage trial for rare swelling disorder | ||
| Di | Richard Pazdur, FDA drug czar, to retire from agency | ||
| Di | FDA details plan to scale back animal tests for some antibody drugs | ||
| Di | Janux sinks on 'overreaction' to prostate cancer data; RFK Jr. replaces ACIP chair | ||
| Di | The 'clever' tool increasingly getting bigger biotech deals signed | ||
| Mo | UK agrees to boost drug prices to dodge US pharma tariffs | ||
| Mo | Regeneron inks gene editing deal with startup Tessera | ||
| Mo | Belite continues ascent as Stargardt drug hits mark in late-stage trial | ||
| Mo | With $130M, Protego pushes forward a new type of amyloidosis drug | ||
| Mo | From feedstocks to infrastructure, Indiana's bioeconomy is on the move | ||
| Mo | Specialty pharmacy's secret weapon: The unsung power of the enrollment form | ||
| Mo | Expanding access in oncology trials: The case for a paired tissue-plasma approach | ||
| 26.11. | Otsuka gains approval for first-of-its-kind treatment against rare kidney disease | ||
| 26.11. | Novartis cuts hundreds of jobs; Novo's dual-acting diabetes drug heading to Phase 3 | ||
| 26.11. | CMS sets 2027 Medicare prices for Wegovy, Trelegy and 13 other drugs |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .